Catheter Precision, Inc. Completes Enrollment of 75 Patients in LockeT-II Study

FORT MILL, SC / ACCESSWIRE / July 25, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US-based medical device company, announced the enrollment of 75 patients in its Phase II LockeT Study, expected to conclude in October 2024.

The LockeT studies began in 2023 to demonstrate product safety and benefits. Phase I, completed in 2023, confirmed LockeT’s functionality and safety. Product roll-out started in early 2024, alongside ongoing Phase II studies.

Phase II compares LockeT to manual compression, evaluating up to 100 patients. The study aims to assess safety, effectiveness, pain reduction, and cost savings. Final data analysis will become available post-October 2024 for peer-reviewed publication.